South Korea · Delayed Price · Currency is KRW QuadMedicine Statistics
Total Valuation
QuadMedicine has a market cap or net worth of KRW 94.38 billion. The enterprise value is 77.47 billion.
| Market Cap | 94.38B |
| Enterprise Value | 77.47B |
Important Dates
The next estimated earnings date is Thursday, September 17, 2026.
| Earnings Date | Sep 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
QuadMedicine has 11.48 million shares outstanding. The number of shares has increased by 14.85% in one year.
| Current Share Class | 11.48M |
| Shares Outstanding | 11.48M |
| Shares Change (YoY) | +14.85% |
| Shares Change (QoQ) | +15.65% |
| Owned by Insiders (%) | 25.71% |
| Owned by Institutions (%) | 4.32% |
| Float | 7.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.65 |
| PB Ratio | 3.51 |
| P/TBV Ratio | 3.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.53 |
| EV / Sales | 7.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.64 |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.28.
| Current Ratio | 2.58 |
| Quick Ratio | 2.46 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.13 |
| Interest Coverage | -21.93 |
Financial Efficiency
Return on equity (ROE) is -46.18% and return on invested capital (ROIC) is -18.60%.
| Return on Equity (ROE) | -46.18% |
| Return on Assets (ROA) | -12.57% |
| Return on Invested Capital (ROIC) | -18.60% |
| Return on Capital Employed (ROCE) | -20.43% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.26 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 12,170.00 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 19.97 |
| Average Volume (20 Days) | 102,216 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, QuadMedicine had revenue of KRW 9.78 billion and -8.13 billion in losses. Loss per share was -797.88.
| Revenue | 9.78B |
| Gross Profit | 9.78B |
| Operating Income | -7.45B |
| Pretax Income | -8.13B |
| Net Income | -8.13B |
| EBITDA | -4.00B |
| EBIT | -7.45B |
| Loss Per Share | -797.88 |
Balance Sheet
The company has 24.46 billion in cash and 7.55 billion in debt, with a net cash position of 16.91 billion or 1,472.77 per share.
| Cash & Cash Equivalents | 24.46B |
| Total Debt | 7.55B |
| Net Cash | 16.91B |
| Net Cash Per Share | 1,472.77 |
| Equity (Book Value) | 26.89B |
| Book Value Per Share | 2,299.33 |
| Working Capital | 16.04B |
Cash Flow
In the last 12 months, operating cash flow was -4.32 billion and capital expenditures -2.34 billion, giving a free cash flow of -6.66 billion.
| Operating Cash Flow | -4.32B |
| Capital Expenditures | -2.34B |
| Depreciation & Amortization | 3.45B |
| Net Borrowing | -372.11M |
| Free Cash Flow | -6.66B |
| FCF Per Share | -579.76 |
Margins
Gross margin is 100.00%, with operating and profit margins of -76.14% and -83.10%.
| Gross Margin | 100.00% |
| Operating Margin | -76.14% |
| Pretax Margin | -83.10% |
| Profit Margin | -83.10% |
| EBITDA Margin | -40.90% |
| EBIT Margin | -76.14% |
| FCF Margin | n/a |
Dividends & Yields
QuadMedicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.85% |
| Shareholder Yield | -14.85% |
| Earnings Yield | -8.61% |
| FCF Yield | -7.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
QuadMedicine has an Altman Z-Score of 4.08 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.08 |
| Piotroski F-Score | 3 |